The CDC published a report on their study conducted on a heat-treated product produced by Cutter which recorded that the preliminary evidence of the effects of heat treatment was that it reduced the potential for transmission of the AIDS virus. Read more about The CDC published a report on their study conducted on a heat-treated product produced by Cutter which recorded that the preliminary evidence of the effects of heat treatment was that it reduced the potential for transmission of the AIDS virus.
An application for high potency Factorate from Armour was declined in July 1984 on the grounds of safety, quality and efficacy. Read more about An application for high potency Factorate from Armour was declined in July 1984 on the grounds of safety, quality and efficacy.
A licence was granted for Haemate P (Heat Treated Factor 8), produced by Behringwerke, subject to a number of conditions. Read more about A licence was granted for Haemate P (Heat Treated Factor 8), produced by Behringwerke, subject to a number of conditions.
In an assessment of Haemate P (Heat Treated Factor 8), Dr Fowler concluded that it was probable that Hepatitis B would be less likely with the heat-treated product than with comparable untreated products. Read more about In an assessment of Haemate P (Heat Treated Factor 8), Dr Fowler concluded that it was probable that Hepatitis B would be less likely with the heat-treated product than with comparable untreated products.
In a letter to Dr Thomas (NIBSC), Pat Thomas (Hoechst) indicated that Hoechst intended to introduce Haemate P to the market, approximately two years after obtaining a product licence. Read more about In a letter to Dr Thomas (NIBSC), Pat Thomas (Hoechst) indicated that Hoechst intended to introduce Haemate P to the market, approximately two years after obtaining a product licence.
Travenol applied for a UK Product Licence for Hemofil-T (Antihaemophilic Factor Human Method Four Heat Treated). Read more about Travenol applied for a UK Product Licence for Hemofil-T (Antihaemophilic Factor Human Method Four Heat Treated).
A.W. Barrell (Travenol) wrote to Professor Bloom, other haemophilia centre directors and the DHSS to say that Travenol could not give an assurance that the heat treated product eliminated the risk of transmission of AIDS since the causative agent for AIDS had not been identified. Read more about A.W. Barrell (Travenol) wrote to Professor Bloom, other haemophilia centre directors and the DHSS to say that Travenol could not give an assurance that the heat treated product eliminated the risk of transmission of AIDS since the causative agent for AIDS had not been identified.
The assessor for an application for a variation to Hemofil product licence noted that there was no evidence to confirm that AIDS was a viral mediated infection and the addition of heat treatment would destroy about 20% of the coagulant activity yield. Read more about The assessor for an application for a variation to Hemofil product licence noted that there was no evidence to confirm that AIDS was a viral mediated infection and the addition of heat treatment would destroy about 20% of the coagulant activity yield.
CSM(B) was unable to recommend a product licence for Hemofil-T. Read more about CSM(B) was unable to recommend a product licence for Hemofil-T.
In February 1985 the heat treated products of Baxter, Alpha, Armour, Cutter and Immuno were all licensed. Read more about In February 1985 the heat treated products of Baxter, Alpha, Armour, Cutter and Immuno were all licensed.